Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal versus intravenous ipilimumab with nivolumab in melanoma
NL-OMON60648Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab and nivolumab in cutaneous melanoma (CM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Peripheral T-cell subset frequencies and activation. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON60648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60648.